Revenue
2020
2024
2025
Design Therapeutics, Inc. (DSGN)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | $226,000 |
| Research & development | $59.1M | $44.4M | $57.1M | $48.6M | $24.8M | $6.1M |
| Operating expenses | $79.5M | $62.4M | $78.2M | $67.6M | $35.8M | $8.6M |
| Operating income | −$79.5M | −$62.4M | −$78.2M | −$67.6M | −$35.8M | −$8.3M |
| Net income | −$69.8M | −$49.6M | −$66.9M | −$63.3M | −$35.5M | −$8.3M |
| Basic EPSper diluted share | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | -$0.52 |
| Diluted EPSper diluted share | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | -$0.52 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 13, 2025Form 4 | William ArsaniDirector | SellCommon Stock · indirect | 217.6K | $5.25 | $1.14M | 1.00M |
| Aug 13, 2025Form 4 | William ArsaniDirector | SellCommon Stock · indirect | 345.0K | $5.25 | $1.81M | 2.65M |
| Dec 18, 2024Form 4 | Prasad DeepaDirector | SellCommon Stock | 3.8K | $6.27 | $23.9K | 20.0K |
| Aug 9, 2024Form 4 | William ArsaniDirector | SellCommon Stock · indirect | 814.9K | $4.25 | $3.46M | 0 |